HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

Antiaggregation Time after Treating Bifurcations

Defining dual antiplatelet therapy (DAPT) seems a never-ending story. We go from trials showing the safety of...
solaci -
Learn More
Antiplatelet

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty

Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual...
solaci -
Learn More
Antiplatelet

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular...
solaci -
Learn More
Antiplatelet

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow...
solaci -
Learn More
Antiplatelet

Can We Prevent Cardiovascular Events without Aspirin?

As regards the use of antithrombotic agents, the risk of bleeding will always be an issue, and...
solaci -
Learn More
Antiplatelet

First Results for Ticagrelor in Elective Coronary Angioplasty

This is one of the first studies on the use of ticagrelor in patients with stable coronary...
solaci -
Learn More
Antiplatelet

What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial

Courtesy of Dr. Alejandro Lakowsky, MTSAC (Full Member of the Argentine Society of Cardiology) The New England Journal...
solaci -
Learn More
Acute coronary syndromes

Elderly Patients with ACS: Clopidogrel or Reduced-Dose Prasugrel?

Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome...
solaci -
Learn More